Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a Study of BMS-790052 with Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Chronic Hepatitis C Genotype 1
2009-010149-29Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of daclatasvir in hepatitis C virus infection, sponsored by Bristol Myers Squibb. Primary endpoint: Safety (SAEs, discontinuations due to AEs, Grade 3-4 laboratory abnormalities). Started Mar 2009; status: completed.
02
Drugs
daclatasvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2009-010149-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010149-29.